Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat extension study in myeloproliferative neoplasms
NCT05223920Phase 2Completed
- Sponsor
- Imago BioSciences, Inc.
- Start
- Dec 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of bomedemstat in essential thrombocythemia (ET), primary myelofibrosis (PMF), sponsored by Imago BioSciences, Inc.. Started Dec 2021; status: completed.
02
Drugs
bomedemstat
03
Conditions
essential thrombocythemia (ET)primary myelofibrosis (PMF)
Beyond the preview
Go deeper on NCT05223920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223920.